Sagimet Previews 52-Week Acne Drug Data Ahead of U.S. Phase 3 Trial Launch
Event summary
- Sagimet to present 52-week data from Ascletis' Phase 3 open-label extension trial of denifanstat in China on September 30, 2026
- U.S. Phase 3 AURORA trial for moderate to severe acne planned to initiate in Q4 2026
- Denifanstat showed continued efficacy improvements beyond 12-week marks in Chinese trial
- AURORA trial will enroll 800 U.S. patients, with 450 adolescents aged 12-17
- Results to be presented at EADV 2026 congress
The big picture
Sagimet's progress with denifanstat comes as the acne treatment market seeks new oral therapies with better safety profiles than existing options. The company's strategic partnership with Ascletis provides valuable Chinese data that could accelerate U.S. development, though it must now demonstrate consistent efficacy in a different patient population. With approximately 10 million Americans affected by moderate to severe acne annually, successful execution of the AURORA trial could position denifanstat as a significant new treatment option.
What we're watching
- Regulatory Pathway
- Whether the positive Chinese data will translate to U.S. regulatory approval expectations
- Market Timing
- The pace at which Sagimet can initiate and complete the AURORA trial to maintain competitive positioning
- Commercial Potential
- How denifanstat's once-daily oral administration could differentiate it in the moderate to severe acne market